×
About 628 results

ALLMedicine™ Hepatitis D Center

Research & Reviews  224 results

Endpoints and new options for treatment of chronic hepatitis D.
https://doi.org/10.1002/hep.32082
Hepatology (Baltimore, Md.); Lok AS, Negro F et. al.

Aug 1st, 2021 - Therapy of chronic hepatitis D still relies on interferon alfa. However, efficacy is limited and better therapies are needed. Disruption of the interactions of HDV with the helper HBV or with the host is providing a new therapeutic paradigm and ne...

Liver-resident bystander CD8+ T cells contribute to liver disease pathogenesis in chron...
https://doi.org/10.1053/j.gastro.2021.07.027
Gastroenterology Kefalakes H, Horgan XJ et. al.

Jul 25th, 2021 - The hepatitis D virus (HDV) causes the most severe form of chronic hepatitis, often progressing to cirrhosis within 5-10 years. There is no curative treatment and the mechanisms underlying the accelerated liver disease progression are unknown. Inn...

Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A sys...
https://doi.org/10.1111/jvh.13577
Journal of Viral Hepatitis; Kamal H, Fornes R et. al.

Jul 23rd, 2021 - Hepatitis D virus (HDV) infection causes a severe chronic viral hepatitis with accelerated development of liver cirrhosis and decompensation, but whether it further increases the risk of hepatocellular carcinoma (HCC) is unclear. We performed a co...

Prevalence of hepatitis delta virus among chronic hepatitis B carriers in a large terti...
https://doi.org/10.1016/j.jcv.2021.104870
Journal of Clinical Virology : the Official Publication O... Beudeker BJB, Voermans JJC et. al.

Jun 29th, 2021 - Hepatitis D virus infection (HDV) is considered the most severe form of viral hepatitis. In this study, we aimed to evaluate the prevalence of HDV infection in a tertiary center of a large, multi-ethnic city in the Netherlands. Moreover, we valida...

One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability du...
https://doi.org/10.1111/apt.16485
Alimentary Pharmacology & Therapeutics; Palom A, Sopena S et. al.

Jun 29th, 2021 - Spontaneous HDV-RNA fluctuations, assessed by nonstandardised in-house assays, have been reported during the course of chronic hepatitis delta (CHD). To evaluate changes in serum HDV-RNA concentrations in untreated CHD patients and correlate these...

see more →

Clinicaltrials.gov  9 results

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
https://clinicaltrials.gov/ct2/show/NCT02577029

Apr 12th, 2019 - This is a multicenter, open-label study of ARC-520 based treatment regimens administered to patients with HBeAg positive or HBeAg negative immune active chronic Hepatitis B Virus (HBV) infection of various genotypes, or patients with Hepatitis D V...

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
https://clinicaltrials.gov/ct2/show/NCT02511431

Sep 25th, 2018 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. We propose to tre...

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
https://clinicaltrials.gov/ct2/show/NCT01088659

Jan 12th, 2018 - This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D. Patients will be randomized to receive 96 weeks of the...

Lonafarnib With Ritonavir in HDV (LOWR-2)
https://clinicaltrials.gov/ct2/show/NCT02430194

Jul 31st, 2017 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Up to forty-five ...

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
https://clinicaltrials.gov/ct2/show/NCT02430181

Jan 20th, 2017 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjec...

see more →

News  17 results

Risk Factors Can Help Spot People Who Need Hep D Screening
https://www.medscape.com/viewarticle/940855

Nov 13th, 2020 - NEW YORK (Reuters Health) - Several risk factors associated with hepatitis D virus (HDV) infection can be used to identify people who should be screened, researchers report. "It was interesting to find that the risk factors that were identified in...

Hepatitis D Virus Coinfection Boosts HBV Healthcare Costs
https://www.medscape.com/viewarticle/922853

Dec 20th, 2019 - NEW YORK (Reuters Health) - Hepatitis delta virus (HDV) infection, which occurs only as a co-infection with acute hepatitis B (HBV) or a superinfection with chronic HBV, is associated with higher healthcare utilization and costs than HBV alone, a ...

HDV combo therapy reduces viral loads
https://www.mdedge.com/gihepnews/article/211868/hepatology/hdv-combo-therapy-reduces-viral-loads?channel=346
Will Pass, MDedge News

Nov 8th, 2019 - BOSTON – For most patients with chronic hepatitis D virus (HDV) infection, combination therapy with lonafarnib, ritonavir, and peginterferon may significantly decrease viral loads, based on interim results from the phase IIa LIFT trial. After 6 mo.

Viral Hepatitis Overview: Osmosis Study Video
https://www.medscape.com/viewarticle/895006

Apr 20th, 2018 - What is the hepatitis virus? Well, the hepatitis virus invades liver cells and causes inflammation in the liver tissue. Five hepatitis viruses are recognized: hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. They all have sligh...

Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure
http://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure

What is the purpose of the Surrogate Endpoint Table? FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs. This table also f...

see more →

Patient Education  1 results see all →